Leerink Partnrs Estimates AxoGen FY2029 Earnings

AxoGen, Inc. (NASDAQ:AXGN) – Analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for AxoGen in a report released on Tuesday, February 25th. Leerink Partnrs analyst M. Kratky anticipates that the medical equipment provider will post earnings per share of $0.38 for the year. The consensus estimate for AxoGen’s current full-year earnings is ($0.29) per share.

Separately, Canaccord Genuity Group upped their target price on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday.

AxoGen Stock Performance

NASDAQ:AXGN opened at $20.01 on Friday. The stock’s 50-day simple moving average is $17.75 and its 200 day simple moving average is $15.08. AxoGen has a twelve month low of $5.55 and a twelve month high of $21.00. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $880.60 million, a PE ratio of -62.53 and a beta of 1.00.

Institutional Investors Weigh In On AxoGen

Several institutional investors have recently added to or reduced their stakes in the business. Divisadero Street Capital Management LP grew its holdings in AxoGen by 2.7% during the 4th quarter. Divisadero Street Capital Management LP now owns 26,972 shares of the medical equipment provider’s stock valued at $444,000 after buying an additional 700 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in AxoGen by 4.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,128 shares of the medical equipment provider’s stock valued at $398,000 after buying an additional 926 shares in the last quarter. Principal Financial Group Inc. grew its holdings in AxoGen by 8.3% during the 4th quarter. Principal Financial Group Inc. now owns 16,000 shares of the medical equipment provider’s stock valued at $264,000 after buying an additional 1,228 shares in the last quarter. Sentry Investment Management LLC grew its holdings in AxoGen by 9.3% during the 3rd quarter. Sentry Investment Management LLC now owns 17,368 shares of the medical equipment provider’s stock valued at $243,000 after buying an additional 1,483 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in AxoGen by 2.7% during the 4th quarter. Rhumbline Advisers now owns 58,232 shares of the medical equipment provider’s stock valued at $960,000 after buying an additional 1,521 shares in the last quarter. 80.29% of the stock is owned by hedge funds and other institutional investors.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.